Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis

According to final data results presented during the 2021 American Society of Hematology Annual Meeting, activin receptor type IIA ligand trap sotatercept is safe and effective in the treatment of anemia among patients with MPN-associated myelofibrosis, both transfusion-dependent (TD) and non-TD and TD patients. Sotatercept demonstrated response rates of 30% and 32% when used alone and in conjunction with a stable dose of ruxolitinib, respectively.